Application of Proteomics to inflammatory bowel disease research: Current status and future perspectives by Assadsangabi, A. et al.
Review Article
Application of Proteomics to Inflammatory Bowel Disease
Research: Current Status and Future Perspectives
Arash Assadsangabi,1,2 Caroline A. Evans ,3 Bernard M. Corfe,2 and Alan Lobo1
1Gastroenterology Unit, Salford Royal Hospital, Salford, UK
2Molecular Gastroenterology Research Group, Academic Unit of Surgical Oncology, Department of Oncology and Insigneo Institute,
University of Sheﬃeld, Sheﬃeld, UK
3Department of Chemical and Biological Engineering, University of Sheﬃeld, Sheﬃeld, UK
Correspondence should be addressed to Caroline A. Evans; caroline.evans@sheﬃeld.ac.uk
Received 17 July 2018; Accepted 8 October 2018; Published 15 January 2019
Academic Editor: Amosy M'Koma
Copyright © 2019 Arash Assadsangabi et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Inﬂammatory bowel disease (IBD) is a chronic relapsing/remitting inﬂammatory illness of the gastrointestinal tract of unknown
aetiology. Despite recent advances in decoding the pathophysiology of IBD, many questions regarding disease pathogenesis
remain. Genome-wide association studies (GWAS) and knockout mouse models have signiﬁcantly advanced our understanding
of genetic susceptibility loci and inﬂammatory pathways involved in IBD pathogenesis. Despite their important contribution to
a better delineation of the disease process in IBD, these genetic ﬁndings have had little clinical impact to date. This is because
the presence of a given gene mutation does not automatically correspond to changes in its expression or ﬁnal metabolic or
structural eﬀect(s). Furthermore, the existence of these gene susceptibility loci in the normal population suggests other driving
prerequisites for the disease manifestation. Proteins can be considered the main functional units as almost all intracellular
physiological functions as well as intercellular interactions are dependent on them. Proteomics provides methods for the large-
scale study of the proteins encoded by the genome of an organism or a cell, to directly investigate the proteins and pathways
involved. Understanding the proteome composition and alterations yields insights into IBD pathogenesis as well as identifying
potential biomarkers of disease activity, mucosal healing, and cancer progression. This review describes the state of the art in the
ﬁeld with respect to the study of IBD and the potential for translation from biomarker discovery to clinical application.
1. Introduction
IBD is an idiopathic chronic condition of unknown aetiol-
ogy with an inﬂammatory gut response to unidentiﬁed trig-
gers. It broadly encompasses two major disease categories,
namely, ulcerative colitis and Crohn’s disease, with a relaps-
ing and remitting course. In ulcerative colitis (UC), the
mucosal inﬂammation aﬀects the rectum with variable
proximal colonic involvement but always in a continuous
fashion. Although it only aﬀects the colon, total colitis
can be associated with a “backwash” ileitis. Crohn’s disease
(CD) is characterised by discontinuous areas of transmural
inﬂammation. Although it can involve any part of the gas-
trointestinal tract, the terminal ileum and proximal colon
are more frequently aﬀected.
IBD is most common in Northern Europe and North
America with a prevalence of approximately 400 per
100,000 in the UK [1, 2]. Low incidence areas include south-
ern Europe, Asia, and most developing countries, although
the rate of the disease is on the rise on these regions [2].
There has been an increase in the number of Scottish chil-
dren diagnosed with IBD since the mid-1990s [3]. Men and
women are aﬀected similarly. There is a bimodal age of pre-
sentation with an initial peak in the second and third decades
of life followed by another peak in the sixth decade [4].
Although the exact pathogenesis of IBD is still unknown,
disturbance in the normal homeostasis between the intestinal
barrier cells (including epithelial, mesenchymal, and immune
cells) and commensal intestinal microbiota in a genetically
susceptible host plays a central role in its development [5].
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A large list of environmental factors, termed the exposome,
have been proposed to have inﬂuence in the pathogenesis
of IBD such as smoking [6], diet [7, 8], medications [9], exer-
cise [10, 11], air pollution [12], breast feeding [13], excessive
sanitation during infancy [14], and psychological stress [15].
The evidence for environmental triggers in IBD has recently
been reviewed in detail with focus on the complex interac-
tions between the exposome, genome, immune system, and
microbiome, concluding that the gut microbiome is central
to the pathogenesis of IBD [16].
Dysbiosis plays an important part in the pathogenesis of
IBD. There are about 1100 prevalent bacterial species in the
normal human gut microbiome with each individual har-
bouring at least 160 such species [17]. A signiﬁcant reduction
in butyrate producing-bacteria and increase in microorgan-
isms with mucin degradation capacity have been observed
in the gut microbiome of patients with IBD [18–20]. There
is signiﬁcant interest in the gut microbiome, with recent ﬁnd-
ings suggesting that mucosa-associated microbiota changes
in Crohn’s disease are more marked than faecal changes
[21]. Whether dysbiosis is a primary or secondary event in
IBD progression remains unclear.
GWAS and immunological studies have conﬁrmed the
important role of both innate and adaptive immunity in
the pathophysiology of IBD [22, 23]. CD is long known
to be mediated by Th1-mediated immune response as
opposed to UC, which triggers a Th2-mediated response
[24, 25]. Th17-mediated proinﬂammatory response via IL-
23/IL-17 pathway as well as ineﬀective anti-inﬂammatory
Treg-mediated response is contributory in IBD pathogenesis
[26, 27]. On the other hand, the role of innate mucosal
immunity such as epithelial barrier integrity, microbial sens-
ing, autophagy, and unfolded protein response is becoming
more evident in regulating an appropriate inﬂammatory
response in IBD [28, 29]. Altered patterns of cytokine pro-
duction from the innate and adaptive immune cells are in
turn responsible for the continuation of intestinal inﬂamma-
tion and associated symptoms, as well as extra-intestinal
manifestations of IBD [30].
There is considerable interest and beneﬁt to the use of
biomarkers for diagnosis and management of IBD. A bio-
marker is deﬁned by the National Institutes of Health
Biomarkers Deﬁnitions Working Group as “a characteris-
tic that is objectively measured and evaluated as an indi-
cator of normal biological processes, pathogenic processes,
or pharmacologic responses to a therapeutic intervention”
[31]. For IBD, biomarkers are of value in diagnostic and
prognostic purposes with the potential to identify treat-
ment strategies for disease management. Biomarkers to
assess intensity of inﬂammation are also of value, as are
those indicating disease course and associated complica-
tions [32]. Furthermore, risk stratiﬁcation of subjects with
a history of IBD into those likely to relapse and those who
will remain quiescent remains a signiﬁcant challenge. Risk
and beneﬁt assessment in IBD treatment is also a major issue
especially as the disease behavior is unpredictably variable
amongst patients; therefore, a reliable predictive biomarker
would be very beneﬁcial in stratifying aggressive immuno-
suppressive treatments to patients at high risk of severe
relapses, while avoiding potential harmful drug exposure to
those with more indolent disease course [32–34].
Protein molecular biomarkers or panels of biomarkers
to form “biomarker signatures” are particularly popular
for noninvasive testing. Proteomics enables biomarker dis-
covery by providing methods for identiﬁcation and quantiﬁ-
cation of proteins and thus comparative proﬁling of complex
biological samples.
2. Proteomics
The term “proteomics” was coined in 1995 from the combi-
nation of genomics and proteins [35]. The proteome is the
entire set of proteins that can be expressed by a genome in
a cell. Proteomics encompasses studies for the identiﬁcation
of all proteins as well as their function and structure.
A general workﬂow applied in nearly all proteomic stud-
ies included in this paper involves sample selection, protein
extraction, protein or peptide preparation, protein/peptide
separation, protein/peptide identiﬁcation and quantiﬁcation,
and statistical treatment of the quantitative data obtained
and the interpretation of the results using bioinformatics
[36, 37]. To date, there is no one method for proteomic
analysis. In order to reduce the complexity of proteomic
investigation, cellular compartmentalisation has been pro-
posed [38]; these smaller cellular compartments are some-
times referred to as “secretome” (investigation of secreted
proteins in bodily ﬂuids or cell culture supernatants), “cell
surface proteome,” “phosphoproteome,” and “interactome”
(investigation of the set of protein-protein interactions taking
place in a cell).
Brieﬂy, identiﬁcation of proteins in proteomics occurs
through the analysis of (i) intact proteins or (ii) protein
fragments termed “top-down” and “bottom-up” approaches,
respectively. Top-down proteomic approaches are particu-
larly suited to analysis of diﬀerent protein products encoded
by a single gene protein. These products are termed pro-
teoforms, a single term per protein to encompass diversity
[39] that can result from genetic variation, alternatively
spliced RNA transcripts, and posttranslational modiﬁca-
tions [40]. Generating an inventory of human proteoforms
and multiproteoform complexes poses signiﬁcant technical
challenges as outlined by Naryzhny [39]. Bottom-up proteo-
mics achieves protein identiﬁcation by analysis of peptide
fragments generated by proteolytic digestion of intact pro-
teins and has been widely employed. Proteomics oﬀers a
versatile toolkit of analytical techniques. Top-down and
bottom-up proteomic analyses yield complementary infor-
mation. There are two core technologies employed in prote-
omic analysis: protein separation and analysis using mass
spectrometry for protein identiﬁcation, characterisation,
and quantiﬁcation. Table 1 provides information on diﬀerent
proteomic techniques, with examples of key applications to
IBD research and original papers describing their imple-
mentation and reviews of their use for clinical proteomics.
For more information, there are review articles that pro-
vide an overview of commonly used proteomic techniques
and workﬂows [41, 42].
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3. Proteomic Techniques
The implementation of proteomic techniques has revolu-
tionised biomarker discovery. For clinical proteomics, the
commonly used quantitative proteomic methodologies are
“gel-based” polyacrylamide gel electrophoresis (PAGE) and
two-dimensional diﬀerence gel electrophoresis (2DE) and
“gel-free” isotope-tagging/labelling technologies, including
iTRAQ (isobaric tags for relative and absolute quantiﬁca-
tion), SILAC (stable isotope labelling with amino acids in cell
culture), and so-called label-free quantiﬁcation [43]. In gen-
eral, gel-free methods can address many of the shortcomings
of gel-based approaches, which is tedious and ineﬃcient in
resolving proteins that are low abundant, insoluble, or large
(200 kDa) [44]. Protein identiﬁcation from 2DE gels requires
excision of individual protein spots of interest and processing
for identiﬁcation by MS, often based on peptide mass ﬁnger-
printing (measurement of peptide mass (mass/charge)) or
MSMS analysis whereby peptides are fragmented to provide
amino acid sequence and or posttranslational modiﬁcation
(PTM) information. Proteins are processed by proteolytic
digestion to generate peptides; information from peptides
is integrated to the protein level. Gel-free separation of pro-
teins is performed at the peptide level, for technical reasons
since peptide separation is more amenable to high through-
put in the liquid phase than for proteins. High-performance
liquid chromatography (HPLC) techniques are employed,
typically reversed-phase HPLC. For complex samples, typi-
cally peptides, fractionation employs an additional HPLC
step prior to reversed-phase HPLC, termed 2D-HPLC,
using a diﬀerent, orthogonal separation chemistry. In this
case, an HPLC or UPLC method is selected to exploit dif-
ferent physico-chemical properties of peptides, e.g., charge
or hydrophobicity, to achieve greater sample fractionation
than can be achieved by reversed-phase HPLC alone, to
boost the number of peptides and thus proteins identiﬁed
in a sample. Such additional fractionation is typically per-
formed oﬀ-line prior to LC-MS or MS/MS analyses.
Proteomic techniques can be divided to two groups [38]:
(1) Discovery proteomics: “unbiased” or “hypothesis-
free” methods where the target protein(s) is unidenti-
ﬁed and the focus is on global protein proﬁling to
identify diﬀerences between samples. These methods
are particularly useful tools for biomarker discovery
when potentially thousands of unknown proteins are
to be investigated. Two-dimensional poly-acrylamide
gel electrophoresis (2DE) and liquid chromatography
(LC) are amongst the common tools used in separa-
tion of a large amount of proteins followed by mass
spectrometry- (MS-) based techniques for relative
quantiﬁcation of proteins
(2) “Targeted” techniques where the protein(s) of interest
is already known. These methods commonly use sen-
sitive antibodies with high aﬃnity for target proteins.
They include protein or tissue microarray and western
blotting (WB) techniques. High-throughput LC-MS
methods include selected reaction monitoring (SRM)
of a predeﬁned series of precursor/product ion pairs,
termed transitions, that are speciﬁc to the protein ana-
lyte. When SRM is applied to investigate multiple
transitions, this method is referred to as multiple reac-
tion monitoring (MRM). A further development of
parallel reaction monitoring (PRM) can also be uti-
lised as a targeted technique, especially for conﬁrma-
tory data, which provided alternatives to traditional
antibody-based methods (Table 1).
The utility of quantitative proteomics, discovery, and tar-
geting, for diagnosis and therapy of human disease, is
reviewed by Cifani and Kentsis [45].
In this review, we have endeavoured to collate all pub-
lished studies on IBD incorporating newer high-throughput
proteomic techniques, through comprehensive electronic
search using “PubMed” website search from 2000 to 2018,
with extra ad hoc reports from older seminal papers in
the subject. The search criteria included combination of
“proteomics,” “mass spectrometry,” and/or “protein array”
with “IBD,” “UC,” “Crohn’s disease,” “Crohn’s colitis,” and/
or “colitis” (last accessed 29th September 2018).
4. Research in IBD
4.1. Bioﬂuid Proteomics in Inﬂammatory Bowel Disease. Bio-
ﬂuids and excrements including faeces, plasma, ascites ﬂuid,
urine, and saliva allow convenient sampling modalities for
biomarkers and patient screening that are indicative of
underlying immunopathophysiologic changes and therefore
are important sources of interest for proteomic analysis [44].
Plasma proteomics comprises identiﬁcation, quantiﬁca-
tion, and further investigation of plasma/serum proteome in
terms of their functions and interactions, both in health and
in disease. It therefore encompasses investigation of secre-
tome, exosome, and cellular proteins released as part of apo-
ptotic vesicles. Its relative ease of sample collection and
corresponding representation of pathophysiological changes
in humans have made plasma proteomics a rapidly expanding
area of interest in biomarker discovery, recommended for its
stability relative to serum by the Human Proteome Organiza-
tion [46]. Studies in IBD have focused on serum proteomics
which represents a diﬀerent form of the blood sample to
plasma: serum is derived from blood that has coagulated,
ﬁbrin clots blood cells, and related coagulation factors are sep-
arated from serum by centrifugation. For plasma analysis, an
anticoagulant such as EDTA or heparin is added before the
removal of blood cells. The presence of ﬁbrinogen and
other clotting factors in plasma results in a higher protein
concentration than serum [47]. These diﬀerences in the
sample matrix require consideration when performing bio-
marker discovery study or evaluating the clinical use of bio-
markers [48]. Complete proﬁling of such complex biological
samples is still unachievable due to the presence of a high
concentration of few proteins and requires depletion; in
particular, albumin, immunoglobulins, serotransferrin, and
haptoglobin represent more than 99% of the total serum
and plasma proteins and interfere with the detection of less
abundant proteins, limiting the analytical eﬃciency of LC-
MS/MS. Therefore, their removal is essential to making
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low-abundant species detectable; a range of immunoaﬃnity
reagents are available, as reviewed by Pisanu et al. [49].
4.2. Human Studies on Bioﬂuids. Meuwis et al. investigated
the sera of patients with IBD, healthy controls, and inﬂam-
matory controls (other than IBD) in order to compare the
proteome proﬁle speciﬁc for each condition. Using surface
enhanced laser desorption ionization-time of ﬂight-mass
spectrometer (SELDI-TOF-MS) technology [50], they suc-
cessfully puriﬁed and identiﬁed four acute-phase reactant
proteins as potential biomarkers of disease activity including
platelet factor 4 (PF4), haptoglobin α2 (Hpα2), ﬁbrinogen-α
chain (FIBA), and myeloid-related protein 8 (MRP8), two
of which (PF4 and Hpα2) were further conﬁrmed through
standard methods. These are all known proteins of acute-
phase inﬂammation, but their diﬀerential distribution
amongst patient groups could help to discriminate IBD from
controls [50]. PF4 belongs to the CXCL chemokine family
also known as chemokine (C-X-C motif) ligand 4 (CXCL4),
produced mainly by megakaryocytes and released at the
injury site when activated [51–53]. Haptoglobin (Hp) is a
multimeric serum protein and is generally used as a marker
of inﬂammation and haemolysis; the molecule consists of
2α and 2β subunits connected by disulphide bridges. Two
haplotypes of Hpα (α1 and α2) exist, which give rise to phe-
notypes Hpα 1-1, Hpα 1-2, and Hpα 2-2. Meuwis et al. dem-
onstrate that the Hpα2 subunit is independent of Hpα1 and β
suggesting this as a new biomarker speciﬁc for IBD [50]. Fur-
ther work by Vanuytsel et al. identiﬁed human zonulin (an
important physiological modulator of paracellular intestinal
permeability) as prehaptoglobin-2 (pre-HPα2), a protein
which is previously regarded as simply the inactive precursor
for HPα2 [54]. Allele HPα2 and genotype HPα 2-2 have been
shown to be overrepresented in diﬀerent immune diseases
like rheumatoid arthritis (RA), systemic lupus erythematosus
(SLE), and type 1 diabetes and in patients with IBD rela-
tive to healthy controls [54–58]. MRP8 and MRP14 are two
abundant cytoplasmic proteins of phagocytes that function
as endogenous activators of Toll-like receptor 4 and thereby
amplify phagocyte activation during inﬂammation upstream
of TNF-α–dependent eﬀects [59]. MRP8, which is the active
component of the MRP8-MRP14 complex, induces intra-
cellular translocation of myeloid diﬀerentiation primary
response protein 88 and activation of interleukin-1 recep-
tor–associated kinase-1 and NF-κB, resulting in an elevated
expression of TNF-α [59]. MRP8 is also part of the calprotec-
tin complex, a biomarker of clinical endoscopic and disease
activity in IBD when quantiﬁed in the stool [60].
In order to assess responders and nonresponders to
inﬂiximab therapy in CD before and after the treatment,
Meuwis et al. exploited serum proteomic proﬁling using
SELDI-TOF-MS technology in a subsequent study, which
showed a positive correlation between PF4 and nonresponse
to inﬂiximab therapy in a post hoc analysis [61].
Kanmura et al. investigated the sera isolated from
patients with UC (both active and inactive), CD, colon
cancer, infectious colitis, and normal control in an attempt
to discover biomarkers of disease activity speciﬁc to each dis-
ease state. They employed protein array technology by
coupling the ProteinChip system with SELDI-TOF/MS for
serum protein proﬁling [62]. They identiﬁed that 3 increased
in abundance proteins, namely, human neutrophil peptides
1-3 (HNP 1-3) (antimicrobial peptides from α-defensin
groups of proteins secreted by neutrophils and phagocytes),
in the serum of active UC patients in comparison to the rest
of the patients’ subgroups including UC in remission, CD,
infectious colitis, and healthy controls. They further con-
ﬁrmed these data using enzyme-linked immunosorbent
assays (ELISA) and proposed HNP 1-3 as new biomarkers
of UC disease activity [62].
To investigate biomarkers speciﬁc for children with IBD,
Vaiopoulou et al. compared sera of adults and children with
CD using 2DE followed by MALDI-TOF-MS and further
validation by western blotting [63]. Ceruloplasmin (the
acute-phase plasma protein produced by activated macro-
phages is a ferroxidase enzyme with bacteriocidal activity
[64]) and apolipoprotein B-100 (APOB) were signiﬁcantly
overexpressed in children, whereas clusterin (a glycoprotein
with antiapoptosis eﬀect) [65] was found to be signiﬁcantly
overexpressed in adults with CD [63]. They further conﬁrmed
the diﬀerential expression of ceruloplasmin and clusterinwith
western blotting. Overexpression of clusterin may reﬂect the
age-related change in the level of this protein irrespective of
CD pathogenesis, as shown by Ignjatovic et al. [66]. The
increase in abundance of APOB in this study contradicts a
previous report by Koutroubakis et al., which showed a lower
level of this protein in serum from a group of adult patients
with CD relative to controls [67]. Whether this new ﬁnding
in a child population suggests an alternative activation path-
way is unknown, although the IL-6 stimulatory eﬀect on the
level of APOBmRNA levels [68] and its elevated serum levels
in the adult and child population with IBD [69, 70] may
explain overexpression of APOB in this study.
Hatsugai et al. investigated peripheral blood mononu-
clear cell proteins from a cohort of 17 UC and 13 CD
patients using 2DE and discriminant analysis (orthogonal
partial least squares-discriminant analysis or OPLS-DA)
with subsequent quantitative MALDI-TOF MS/MS analysis
in a search for a diﬀerential proteome signature between
UC and CD [71]. They identiﬁed a model of 58 protein
spots, which could discriminate between UC and CD
with good performance for diﬀerentiation (R2 = 0 948) and
prediction of the diseases (Q2 = 0 556). They further suc-
cessfully identiﬁed 11 out of 58 protein spots by MS/MS
analysis, which were assigned to seven kinds of proteins
including Annexin A6 (ANXA6), peroxiredoxin 2 (PRDX2),
a/b-hydrolase domain-containing protein 14B (ABHD14B),
cyclophilin A (peptidyl isomerase A, PPIA), carbonic anhy-
drase 2 (CA2), beta actin (ACTB), and protein S100A9
(S100A9). ANXA6, PRDX2, ABHD14B, and PPIA were
increase in the UC patients compared to the CD patients,
of which the increase of PRDX2, ABHD14B, and PPIA was
statistically signiﬁcant. In contrast, CA2, ACTB, and
S100A9 were found to be decreased in abundance in the
UC patients compared to the CD patients, of which only
the decrease in ACTB was statistically signiﬁcant [71].
Four of the identiﬁed proteins were found to be associated
with inﬂammation and oxidation/reduction (PPIA, S100A9,
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PRDX2, and CA2), and the remaining three were associ-
ated with the formation of the cytoskeleton (ACTB), endocy-
totic traﬃcking (ANXA6), and activation of transcription
(ABHD14B). They did not match their protein spot analysis
for diﬀerent stages of UC/CD disease activity from the outset;
hence, their proposed model based on a wide disease activity
index range (SCCAI range 4-15 for UC and IOIBD score
range 0-6 for CD)makes this discriminatory tool less predict-
able and reproducible.
Gazouli et al. investigated diﬀerential serum protein
levels corresponding to the degree of inﬂiximab responsive-
ness in a small group of CD patients using 2DE and
MALDI-TOF-MS proteomic methods [72]. They identiﬁed
a panel of increased-in-abundance proteins in the primary
inﬂiximab nonresponsive group including apolipoprotein
A-I (APOA1), apolipoprotein E (APOE), complement C4-B
(CO4B), plasminogen (PLMN), serotransferrin (TRFE),
beta-2-glycoprotein 1 (APOH), and clusterin (CLUS) in com-
parison to the inﬂiximab-induced remission group. They
further conﬁrmed CLUS and APOA1 overexpression in the
primary nonresponder group by WB. Moreover, leucine-rich
alpha-2-glycoprotein (A2GL), vitamin D-binding protein
(VTDB), alpha-1B-glycoprotein (A1BG), and complement
C1r subcomponent (C1R) were signiﬁcantly increased in
abundance in the serum of the inﬂiximab-induced remission
group as compared to the baseline pre-inﬂiximab treatment
serum [72]. It should be noted that this was a single-centre
study with limited patient number and no further conﬁrma-
tion of the results in an independent group of patients.
In order to evaluate the speciﬁc changes in serum peptide
abundance, Nanni et al. fractionated low molecular weight
(LMW) serum proteins with a 10kDa cut-oﬀ from patients
with clinically active CD (n = 15; CDAI > 150) and healthy
controls (n = 48) and utilised a reversed-phase nano-LC ESI/
Q-TOFMS approach combined with targetedMS/MS analysis
[73]. Fibrinopeptide A (FPA) (a peptide released from ﬁbrin-
ogen during clotting of the blood), peptides from complement
3 protein (C3) and its fragment (C3F), and peptides from
apolipoprotein A-IV were identiﬁed as the peptides whose
concentration mostly increases in CD in this study. Previ-
ous studies have demonstrated the anti-inﬂammatory eﬀect
of apolipoprotein A-IV in DSS-induced murine colitis
in vivo [74] and considered it as an independent predictor of
disease activity in patients with IBD [75]. Although the diﬀer-
ential LC–MS analysis was performed only on the LMW pro-
teome enriched during the preanalytical step, all the identiﬁed
proteins in the study had a MW much higher than 10kDa
[73]. Therefore, they proposed a speciﬁc exoprotease activity
in CD that involves procoagulant peptides as substrates (ﬁbri-
nopeptide A) and postulated that platelet-derived microparti-
cles (PDMPs) may contain yet unidentiﬁed exopeptidase
enzymes with proinﬂammatory properties [73].
4.3. Animal Studies on Bioﬂuids. In a murine model of IBD
using interleukin-10 knockout (IL-10−/−) mouse, Viennois
et al. performed a longitudinal study of circulating serum
proteins using 2D GE and MALDI-TOF/TOF MS [76].
Female IL-10−/− mice were monitored for colitis develop-
ment for 15 weeks: at weaning (day 30) (no colitis), 15 weeks
post-weaning (day 135) (severe colitis), and at an intermedi-
ate time point (day 93) (mild colitis). They identiﬁed and fur-
ther conﬁrmed (via WB or ELISA) a panel of 12 protein
biomarkers, which could diﬀerentiate serum samples in mid-
to late-stage IL-10−/− mice from early noninﬂamed IL-10−/−
mice. The proteins were involved in a range of biological
processes such as gene expression, glycosylation, signal trans-
duction, metabolism, cell diﬀerentiation, translation, phos-
phorylation, immune response, protein denaturation, aging,
and menopause. Of note, alpha-1-B glycoprotein (A1BG)
was also decreased, whereas haptoglobin (HP), pregnancy
zone protein (PZP), and hemopexin (HPX) were increased
throughout the colitis progression in IL-10−/− mice. Peroxire-
doxin 2 (PRDX2) was transiently increased during mild colitis
development, whereas transferrin (TF) was only increased
later in severe colitis mice. In order to compare the IL-10−/−
chronic colitis model to a model of acute colitis, the above con-
ﬁrmed biomarkers were trialled in a DSS mouse model of
acute colitis; PZP and PRDX2, previously found to be
increased in colitic IL-10−/− mice, were not altered in mice
treated with DSS, suggesting that these markers are speciﬁc
to a chronic inﬂammatory state. A1BG was observed to be
decreased after DSS treatment, and HP and HPX were drasti-
cally increased, showing that A1BG, HP, and HPX were
altered in the same way as was previously observed in colitic
IL-10−/− mice. To investigate the speciﬁcity of these bio-
markers to intestinal inﬂammation, they further explored
these proteins in a model of extraintestinal inﬂammation with
collagen antibody-induced arthritis (CAIA). The overall out-
come showed that PZP, COL1A1, and PRDX2 were speciﬁc
to intestinal inﬂammation development with PZP and PRDX2
being speciﬁc to the IL-10−/− model. The serum amyloid
P-component and transthyretin were speciﬁc to the develop-
ment of arthritic inﬂammation, whereas HP, inter-alpha-
trypsin inhibitor heavy chain 4 (ITIH4), HPX, complement
component 3 (C3), and A1BG were found to have an altered
level in any inﬂammatory conditions.
4.4. Tissue (Cell) Proteomics in Inﬂammatory Bowel Disease.
The application of cellular proteomics in IBD has been inves-
tigated in several studies using surgical or endoscopic colonic
tissue biopsies, as well as cultured colonic cell lines [77].
4.5. Human Studies Using Tissues. Distinguishing UC and
Crohn’s colitis in clinical settings may be important as this
may aﬀect the medical and surgical management plan - par-
ticularly when considering panproctocolectomy and ileo-
anal pouch surgery in a colitic patient. The diﬀerentiation
can be very diﬃcult despite all available clinical, radiological,
endoscopic, and histological criteria; consequently, about
15% of colitic patients are being labeled as “indeterminate
colitis” due to inconclusive investigation outcomes and
change of diagnosis from UC to Crohn’s colitis occurs in
another 15% following colectomy [78].
In an attempt to discover a more sensitive diﬀerentiat-
ing diagnostic tool between Crohn’s colitis (CC) and UC,
M’Koma et al. investigated the ability of histology-directed
MALDI-MS to determine the proteomic patterns between
each group in a pilot study [78]. They compared uninﬂamed
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versus inﬂamed submucosa in UC and CC groups separately
using MALDI-MS to determine whether this method can
distinguish inﬂammation in each group. They then com-
pared the proteomic outcomes from inﬂamed submucosa in
UC and CC, uninﬂamed submucosa in UC and CC, and
inﬂamed mucosa in the two groups to determine whether
this method could distinguish UC and CC. They utilised a
histology-directed protein proﬁling previously described
[79] in order to separate inﬂamed and uninﬂamed areas in
mucosa and submucosa accordingly. Pairwise comparative
analyses of the clinical groups obtained from MALDI-MS
(comparing the discrete protein peaks in each group) were
able to distinguish CC and UC specimens by proﬁling the
colonic submucosa only [78]. They did not identify the
potential discriminatory proteins in MS spectral peaks. Fur-
thermore, the small sample size of 51 patients (n = 24CC
and n = 27UC) made the estimation of statistical signiﬁcance
of the intergroup diﬀerences approximate. Using the same
histology-directed MALDI-MS methodology, the group
recently analysed histologic layers of 62 conﬁrmed IBD tissues
(26 from CC and 36 fromUC) in order to distinguish between
UC and CC [80]. A total of 1257 spectra from 62 total IBD
cases were used for statistical analysis of the mucosa. Out of
312 total peaks in the averaged spectra, 114 were found to have
Wilcoxon rank-sum p values of less than 0.05 [80]. A support
vector machine algorithm consisting of 25 peaks was able to
discriminate spectra from CC and UC with 76.9% spectral
accuracy when using a leave-20%-out conﬁrmation of the
results. The application of the model to the entire dataset
resulted in an accurate classiﬁcation of 19/26 CC patients
and 36/36 UC patients when using a 2/3 correct cut-oﬀ
[80]. Whether this discriminatory methodology can be used
to diﬀerentiate UC from CC in patients with indeterminate
colitis needs further investigation, as none of the patients
recruited in this study previously had an equivocal diagnosis.
In a pilot study by Shkoda et al., IEC puriﬁed from
colonic and ileal regions of surgically resected tissues in UC
(n = 6) and CD (n = 6) were compared to normal-looking
tissue from colon cancer patients (n = 6). 2D SDS-PAGE
analysis was combined with peptide mass ﬁngerprinting via
MALDI-TOFMS. Amongst the proteins found with diﬀeren-
tial expression in both UC and CD groups, statistical sig-
niﬁcance was reached for 4 proteins including L-lactate
dehydrogenase, carbonyl reductase (NADPH prostaglandin
E2 reductase), keratin 19, and the Rho-GDP dissociation
inhibitor R (Rho GDI α) [81]. Western blotting further
conﬁrmed the MS data regarding induced expression of
Rho GDI α in inﬂamed mucosa from both patient groups
in comparison to control, but this overexpression was also
observed in the mucosa from patients with sigmoid divertic-
ulitis suggesting that this latter change in Rho GDI α overex-
pression is probably due to inﬂammation rather than the
IBD-speciﬁc process [81]. They further compared inﬂamed
colonic mucosa to the noninﬂamed mucosa in two sepa-
rate UC patients. Although there was a signiﬁcant variation
between the number of diﬀerentially expressed proteins (28
versus 3), the most signiﬁcant changes in protein expression
were detected for Annexin A2 and programmed cell death
protein 8 in these two patients [81]. Lactate dehydrogenase
is a cellular tissue enzyme that catalyses the conversion of
pyruvate (the end product of glycolysis) to lactate in hypoxic
states and hence is a general marker of tissue injury and
damage. Increased carbonyl reductase (an oxidoreductase
enzyme utilising NADP/NAD as cofactor) expression is also
suggestive of increased oxidative burst in the colonic mucosa
during inﬂammation [82]. Intermediate ﬁlaments (IF) are
one of the main components of the human cell cytoskeleton,
which mainly consist of keratins. Keratins 8, 18, and 19
constitute the main keratins in the intestinal epithelial
cells. Our group has recently shown a reduced level of kera-
tins 8, 18, and 19 in the insoluble fraction of active colonic
mucosa of UC patients in comparison to proximal inactive
mucosa from the same patients as well as normal controls
[83–85]. Rho GDI (a modulator of Rho-GTPase family of
enzymes [86]) complexed with RhoA has recently been
shown to be involved in NF-κB activation cascade [87].
Annexin A2 is a pleiotropic protein from the calcium-
dependent phospholipid-binding protein family that orches-
trates a growing spectrum of biologic processes including
involvement in cellular growth and in signal transduction
pathways [88]. In a recent study by Zhang et al. published
in Chinese language (the abstract is available in English),
Annexin A2 expression has been shown to be upregulated
in inﬂamed UC mucosa in comparison to normal control
using the immunohistochemistry technique followed by Q-
PCR to conﬁrm mRNA overexpression of Annexin A2 [89].
Programmed cell death protein 8, otherwise known as cas-
pase 8, has been shown to control necroptosis of Paneth
cells and potentially the death of intestinal epithelial cells in
patients with Crohn’s disease and hence to participate in
the mucosal inﬂammation process [90]. The use of normal-
looking colon tissues from colon cancer patients as a control
group may cause potential spurious results considering the
previous study by Polley et al., which indicated that protein
expression in the apparently normal colonic mucosal ﬁeld
is modiﬁed in individuals with neoplastic lesions at sites dis-
tant from the lesion, indicative of a ﬁeld eﬀect [91].
In order to explore the protein proﬁle in UC, Fogt et al.
deployed proteomic analysis (2D PAGE followed by LC-
MS/MS) on surgically resected colonic tissue from 5 patients
with active UC comparing active resected mucosa/submu-
cosa to the uninvolved grossly normal mucosa of the UC
patients [92]. Increased abundance of proteins in the active
UC tissues that are mainly involved in inﬂammation and
repair included protocadherins (a subtype of the cadherin
superfamily of proteins involved in cell adhesion and the
cell-cell interaction process. These ﬁndings were linked to
the retention of the monolayer morphology of proliferat-
ing cells [93, 94]), α-1 antitrypsin (a protease inhibitor and
acute-phase response protein [95]), tetratricopeptide repeat
domains (associated with heat shock proteins [96]), caldes-
mon (a calmodulin-binding protein; calmodulin is in turn a
regulator of gap junction channels [97]), and mutant desmin.
The presence of mutated desmin (a type III intermediate
ﬁlament) was conﬁrmed by western immunoblotting. The
authors hypothesized the possibility that desmin mutation
may be a primary or secondary feature in the pathogenesis
of UC, although it could also represent a random mutation
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in a high-turnover cell population [92]. In a recent genetic
analysis study by Avitzur et al., tetratricopeptide repeat
domain 7A mutations have been linked to very early onset
IBD as a result of severe apoptotic enterocolitis due to defects
in enterocytes and T cells [98].
Hsieh et al. used 2D PAGE and MALDI-TOF-MS for
peptide mass ﬁngerprinting (PMF) analysis in colonic tissue
biopsies from 4 patients with active chronic UC, 3 patients
with infectious colitis, and 5 normal individuals to explore
diﬀerentially expressed proteins in UC [99]. They identiﬁed
19 distinct proteins including 13 decreased-in-abundance
and 6 increased-in-abundance proteins in the active com-
partment of the UC mucosa. Of the 13 decreased-in-
abundance proteins in the active UC colonic mucosa, eight
were either the mitochondrial component proteins or pro-
teins directly involved in oxidation/phosphorylation [99].
These results were conﬁrmed using immunoblotting analy-
ses and immunohistochemical (IHC) studies. They further
compared active distal UC mucosa with proximal normal-
looking inactive mucosa in two patients using similar pro-
teomic analysis and observed relatively similar protein
expression patterns between inactive UCmucosa and normal
colonic mucosa except for downregulation of prohibitin
(PHB) (the major component protein of the mitochondrial
inner membrane) in inactive UCmucosa similar to the active
distal UC compartment. The authors hypothesized the piv-
otal role of mitochondrial dysfunction in the pathogenesis
of UC [99]. PHBs are members of a highly conserved protein
family that are found in multiple cellular compartments
including the mitochondria, nucleus, and the plasma mem-
brane [100]. Nuclear and mitochondrial PHBs are thought
to be involved in cellular diﬀerentiation, antiproliferation,
morphogenesis, and cellular survival (through the Ras-Raf-
MEK-Erk pathway) and in particular maintenance of the
functional integrity of the mitochondria and protection of
cells from various stresses [100]. Using a yeast two-hybrid
method, Bacher et al. identiﬁed PHB as a binding partner
for Annexin A2 and α-actinin, which further attribute their
interactions with members of the cytoskeletal proteins [101].
In order to characterise the diﬀerential proteins associ-
ated with inﬂamed mucosa in active UC, Poulsen et al. inves-
tigated tissue biopsies from active distal UC patients using
2DE and MALDI-TOF MS technology [102]. They com-
pared the whole lysate extract isolated from active rectal
UC mucosa and reciprocal inactive proximal mucosa from
the same patient groups and identiﬁed 222 statistically signif-
icant protein spots using image analysis. Protein proﬁles
from diﬀerent colonic regions of normal control individuals
were compared to identify proteomic changes reﬂecting
inﬂammatory status of the colon rather than position spe-
ciﬁc eﬀects. The data showed a generally similar proteomic
signature in rectum and left colon ﬂexure except for alpha-
enolase and hydroxymethylglutaryl–CoA synthase, which
had diﬀerential protein levels between rectum and left
colon ﬂexure in both patients and normal control individ-
uals suggesting that the two latter proteins are proteins
associated to segment sampling rather than potential dis-
ease markers [102]. Principal component analysis (PCA)
grouped noninﬂamed samples separately from the inﬂamed
samples suggesting a distinctive proteomic signature of the
colon mucosa in acute UC. A total of 43 individual protein
spots were identiﬁed corresponding to 33 individual proteins.
These proteins included those involved in energy metabolism
(triosephosphate isomerase, glycerol-3-phosphate dehydro-
genase, alpha enolase and L-lactate dehydrogenase B-chain,
isocitrate dehydrogenase, inorganic pyrophosphatase, and
enoyl-CoA hydratase) and in oxidative stress (superoxide
dismutase, thioredoxins, and selenium-binding protein)
[102]. The authors hypothesized that diﬀerent protein pro-
ﬁles of several glycolytic enzymes and other proteins involved
in energy may indicate inﬂammation-associated alterations
in energy metabolism in UC patients, which could in turn
be related to malfunction of the utilisation of n-butyrate
(the preferred source of energy for colonocytes in the distal
colon [103]). They further postulated that the observed low-
ered enoyl-CoA hydratase in inﬂamed tissue might infer
impaired fatty acid oxidation; the state of energy deﬁciency
is further strengthened by change in the glycolytic pathway
reﬂected as a higher expression of glycolytic enzymes in
inﬂamed mucosa [102].
In an attempt to ﬁnd speciﬁc biomarkers in IBD includ-
ing its subtypes, Han et al. investigated a small number of
patients with active (n = 4) and inactive (n = 4) UC, active
(n = 3) and inactive (n = 3) CD, and inﬂammatory polyps
associated with UC (n = 2) as well as normal controls
(n = 3) using label-free LC-MS analysis [104]. Bone marrow
proteoglycan (PRG2), L-plastin 1 (LCP1), and proteasome
activator subunit 1 (PSME1) were identiﬁed potential bio-
markers for active CD. Following comparison to other
published data, they further summarised certain proteins
in active UC patients to be increased in abundance relative
to normal controls. Candidate biomarkers were Tau tubulin
kinase 2 (TTBK2), spectrin repeat containing nuclear
envelope 2 (SYNE2), succinate CoA ligase 2, GDP-forming
subunit (SUCLG2), and periostin (POSTN), as well as
other proteins that are increased in both active UC and
CD relative to normal tissues including ﬁbrinogen, calpro-
tectin (S100A8), myeloperoxidase (MPO), and neutrophil
defensin-1 (DEFA1B and DEFA1) [104]. It is worth men-
tioning that the diﬀerentiation between active and inactive
UC/CD in this study was based on clinical and endoscopic
ﬁndings. The number of patients included in the study was
another limitation of the study. PRG2 comprises the crystal-
loid core of the eosinophil granule, which has cytotoxic and
microbicidal activities [105]. The protein is an enhancer of
natural killer cell activity [106]. A preform of PRG2 also acts
as a proteinase inhibitor, reducing the activity of pregnancy-
associated plasma protein A (PAPPA) [107]. LCP1, one of
three isoforms of the plastin protein family, is constitutively
expressed at high levels in haemopoietic cell types as well
as many types of solid tissue malignant cells [108, 109]. As
a leukocyte-speciﬁc protein, LCP1 cross-links actin ﬁla-
ments into tight bundles, increasing the stability of actin-
based structures such as podosomes and lamellipodia [110].
PSME1 is a multicatalytic proteinase complex that cleaves
peptides in an ATP/ubiquitin-dependent process (ubiqui-
tin-proteasome system) [111]. It may also harbour a reg-
ulatory role on the Rho GTPase activity [112]. Further
9Gastroenterology Research and Practice
investigation by Bennike et al. used a label-free (LFQ)
proteomic analysis to compare UC to normal biopsies
(n = 10, for each) and identiﬁed proteins with statistically sig-
niﬁcant altered abundance in the UC biopsies to be from
neutrophils and associated with the formation of neutrophil
extracellular traps (NETs) [113]. An increased abundance
of neutrophils and the presence of neutrophil extracellular
traps were conﬁrmed by microscopy and the presence of
extracellular DNA present in the UC colon tissue, suggesting
stimulation of innate immunity [113], since NETS form part
of the ﬁrst line of immune defence [114].
In order to investigate diﬀerential proteomic changes
in UC and tuberculosis colitis (TC), Kwon et al. exam-
ined colonic tissues from these two groups (n = 6 in each
group) in comparison to normal controls (n = 6) using
2DE and MALDI-TOF/TOF MS technology [115]. Of the
over 1000 proteins isolated, mutant β-actin, α-enolase, and
Charcot-Leyden crystal proteins were found to be diﬀerently
abundant in these colitides relative to normal controls. In
particular, α-enolase was signiﬁcantly overexpressed in TC
compared with normal tissue, but underexpressed in UC
relative to control, suggesting α-enolase as a candidate
biomarker for diﬀerential diagnosis of TC and UC [115]. Pre-
vious studies have shown upregulation of α-enolase mRNA
levels in IBD [116] and downregulation at the protein level
in UC [117], which may in turn be partly related to overex-
pression of α-enolase reactive antibodies found in 10-50%
of patients with UC [116, 118]. Although the study suggested
recruiting patients with active colitis, severity of disease activ-
ity was not quantiﬁed. Moreover, there was no conﬁrmation
of the results of the ﬁndings on a new set of tissue samples in
these cohorts.
To identify molecular signatures in UC, Zhao et al.
compared intestinal mucosa from 12 UC patients with 12
normal controls using comparative proteomic analysis with
2DE and MALDI TOF/TOF MS [117]. A total of 26 unique
diﬀerential proteins were identiﬁed, including 12 increased-
in-abundance and 14 decreased-in-abundance in the UC
group. A diﬀerential protein cluster, consisting of 11 proteins
(including Cdc42, vimentin, Annexin A2, HSP90B1, LSP1,
GRP78, and cathepsin D that were increased in abundance
in UC; and HSF2, galectin-3, VDAC-1, and MAWBP that
were decreased in abundance) involved in the p38 mitogen-
activated protein kinase (MAPK) pathway was deduced and
conﬁrmed by western blot. Furthermore, three proteins elic-
ited from the protein cluster (phosphorylated p38, MAWBP,
and galectin-3) were analysed by IHC on 58 UC and 60
normal tissue samples. Increased expressions of p-p38 and
decreased-in-abundance MAWBP and galectin-3 were
detected in active UC compared to normal samples [117];
hence, they concluded that the P38 MAPK pathway might
be involved in UC disease activity. This observation was con-
sistent with data from a DSS-induced experimental colitis
murine model [119]. Others have proposed that the regula-
tion of TNF-alpha, a key mediator in the inﬂammatory pro-
cess in IBD, is interconnected with MAPK pathways [120].
Brentnall et al. applied the quantitative proteomic tech-
nique using LC MS/MS and iTRAQ labelling to study the
protein expression of UC neoplastic progression [121]. They
compared the proteomes of both dysplastic and nondysplas-
tic mucosa from UC patients with high-grade dysplasia or
cancer (UC progressors; n = 5 in each) to the colonic mucosa
of UC patients who were dysplasia-free (UC nonprogressors;
n = 5) and normal non-UC colon (n = 5) in order to inves-
tigate the possibility of ﬁeld defect at the proteome level.
They identiﬁed diﬀerential protein expression relating to
mitochondria; oxidative activity and calcium-binding pro-
teins are associated with UC neoplastic progression. Network
analysis discovered that Sp1 and c-myc proteins might play
roles in UC early and late stages of neoplastic progression,
respectively. Two increased in abundance mitochondrial
proteins in the UC progressor groups, namely, CPS1 and
S100P, which were further conﬁrmed by IHC experiment
on 17 tissue samples. The S100 proteins are a multi-gene
calcium-binding family comprising 20 known human mem-
bers with a broad range of intracellular and extracellular
functions, including regulation of protein phosphorylation
and enzyme activity, calcium homeostasis, regulation of cyto-
skeletal components, and regulation of transcriptional fac-
tors [122]. A previous study by Fuentes et al. suggested that
S100P is overexpressed in colon cancer relative to normal tis-
sue and that S100P stimulates colon cancer cell growth,
migration, Erk phosphorylation, and NF-κB activation
in vitro [123]. CPS1 is a mitochondrial enzyme involved in
the urea cycle and expressed mainly in intestinal epithelial
and liver cells; it detoxiﬁes ammonia and, together with other
enzymes of the urea cycle, is the de novo source of arginine
[121]. Variations in the supply of arginine, due to alterations
in urea cycle function, aﬀect the production of nitric oxide
[124]. Nitric oxide, in turn, can cause DNA damage and
laxity in DNA repair and is associated with inﬂammation-
associated cancers [125]. In this study, they proposed that
the proteome of the nondysplastic mucosa from the pro-
gressor group was more akin to the proteome of high-
grade dysplasia than it was to the nondysplastic mucosa
of the nonprogressor group and concluded that there are
changes in protein expression early in the neoplastic pro-
gression, before the histologic changes become evident in
the epithelial cells.
In the search for objective biomarkers of dysplasia in
UC, the collaborators from the same group (May et al.)
investigated individual rectal and colonic epithelial frac-
tions from UC patients with dysplasia or cancer (UC pro-
gressors) compared to similar samples from patients with
no dysplasia/cancer (UC nonprogressors) in a label-free
MS experiment coupled with HPLC [126]. Mitochondrial
proteins, cytoskeletal proteins, RAS superfamily, proteins
relating to apoptosis, and metabolism were the important
protein pathways diﬀerentially expressed in the nondysplas-
tic and dysplastic tissues of UC progressors, suggesting their
importance in UC neoplastic progression. They further
conﬁrmed two diﬀerentially expressed mitochondrial pro-
teins including TNF receptor-associated protein 1 (TRAP1),
which displayed increased IHC staining in UC progressors
(in both dysplastic and nondysplastic tissue), and CPS1,
which showed a statistically signiﬁcant diﬀerence in IHC
staining between the nonprogressor and progressor groups
[126]. TRAP1 is a mitochondrial heat shock protein involved
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in protection against oxidative stress and apoptosis. Previous
studies have also shown increased expression of TRAP1 in
colorectal carcinoma [127].
In order to identify disease-speciﬁc autoantigens in
CD, Zhou et al. applied immunoproteomic techniques
using a combination of 2D PAGE, WB, and MALDI MS on
surgically obtained mucosal lesions from 8 active CD patients
[128]. Mixed serum samples from the same CD patients
were used as a primary antibody source for detection of
autoantigens in the colonic tissue. The adjacent normal-
looking mucosa on each patient was used as a control to
identify increased protein spot intensities on each gel. They
identiﬁed 6 diﬀerentially expressed protein spots including
prohibitin, calreticulin, apolipoprotein A-I, intelectin-1, pro-
tein disulphide isomerase, and glutathione s-transferase pi.
Prohibitin and glutathione s-transferase overexpression in
the mucosal lesion of active CD patients relative to the neigh-
bouring normal mucosa was further conﬁrmed withWB on 4
separate CD patients [128]. A small number of CD patients
together with lack of controlled patients and follow-up data
were the main limitations of this study.
4.6. Cell Line Studies. Araki et al. compared UC-associated
cancer and sporadic colon cancer cell lines using proteomic
analysis with 2D GE and LC-MS/MS in the search for dif-
ferentially expressed proteins in the two groups and found
a higher expression of heat shock protein of 47 kDa
(HSP47) in UC-associated cancer cell lines [129]. IHC vali-
dation of the result on 63 UC-associated lesions and 81 spo-
radic colon tumour lesions conﬁrmed signiﬁcantly higher
levels of HSP47 in UC-associated colon cancers than in
sporadic counterparts, the expression increasing with a pro-
gression of neoplastic lesions. HSP47 coexpression with type
I collagen in the cytoplasm was further conﬁrmed by double
immunoﬂuorescence staining of cell lines [129]. HSP47
is a collagen-binding, stress-inducible protein localised in
the ER that participates in intracellular processing, fold-
ing, assembly, and secretion of procollagens, especially in
collagen-secreting cells, such as ﬁbroblasts [130]. In tissue,
although HSP47 was found to be expressed in both epithelial
and stromal cells within cancers, only the former showed an
increase with progression to greater malignancy [129].
Barceló-Batllori et al. evaluated homogenates from DLD-
1 colorectal adenocarcinoma cells (as in vitro IBD model)
before and after exposure to IFN-γ, IL-6, and IL-1 and uti-
lised 2D PAGE together with MALDI-TOF-MS in a search
for cytokine-regulated proteins in intestinal epithelial cells
(IEC) in IBD [131]. Amongst several identiﬁed proteins in
the in vitro model (including tryptophanyl-tRNA synthetase,
indoleamine 2,3-dioxygenase, heterogeneous nuclear ribonu-
cleoprotein JKTBP, interferon-induced 35 kDa protein, pro-
teasome subunit LMP2, and argininosuccinate synthetase),
overexpression of indoleamine-2,3-dioxygenase (IDO) was
conﬁrmed in the puriﬁed IEC from IBD patients in compar-
ison to normal mucosa [131]. Indoleamine-2,3-dioxygenase-
1 (IDO1), which is well-characterised in the gut, is the ﬁrst
and rate-limiting step in tryptophan catabolism along the
kynurenine pathway [132]. IDO expression has been linked
with immune tolerance at the maternal-foetal interface via
suppression of T cell proliferation by seminal work of Munn
et al. [133, 134]. Matteoli et al. later observed that CD103+
gut dendritic cells expressing IDO1 support regulatory T-
cell conversion while suppressing Th1/Th17 diﬀerentiation
to promote oral tolerance and limit gut inﬂammation [135].
IDO1 expression is stimulated by inﬂammatory cytokines
including IFN-γ, TNF-α, and IL-1B [132]. Consistent with
this, IDO1 is one of the highly upregulated genes in human
IBD [136].
4.7. Animal Models. Liu et al. studied alteration of lympho-
cytic protein proﬁles in a rat model of 2,4,6-trinitrobenzene
sulfonic acid- (TNBS-) induced colitis [137]. After extracting
proteins from the harvested lymphocytes 7 days post-TNBS/
ethanol colitis induction, they compared protein spots on 2D
PAGE in lymphocytes from colitic and control rats using
PDQuest 2D image analysis followed by identiﬁcation of
diﬀerentially expressed protein spots using MALDI-TOF-
MS. The identiﬁed diﬀerentially expressed proteins were
conﬁrmed with reverse-transcription polymerase chain reac-
tion (RT-PCR). There were 26 proteins that altered in abun-
dance of which 17 and 9 were increased or decreased in
abundance, respectively. Proteins involved in the regulation
of the cell cycle, cell proliferation, and signaling transduc-
tion were increased (NDPKs and E2N), and the one involved
in inﬂammation (MRP14) was increased. Altered proteins
include those associated with apoptosis (increased-in-
abundance IL-12 p40, decreased-in-abundance proteasome
activator complex subunit 2, CARD, and PYD domain-
containing protein) and metabolic/oxidative stress response
(increased-in-abundance ATP-citrate synthase, phospho-
glycerate mutase, and dismutase) activities, as well as others
[137]. Nucleoside-diphosphate kinase (NDPK) catalyses the
phosphorylation of nucleoside diphosphate to nucleoside
triphosphate; it confers protection from cell death by Bax
and alters the cellular levels of several antioxidant enzymes
including Gpx5 [137, 138]. Ubiquitin-conjugating enzyme
(E2N) plays a role in the error-free DNA repair pathway
and contributes to the survival of cells after DNA damage
[137]. Its action has been linked to the regulation of acti-
vating transcription factor 2 (ATF2) and NF-kappa B tran-
scriptional activator precursor p105, which are in turn
essential players in lymphocyte activation [139, 140].
Myeloid-related protein- (MRP-) 8 (S100A8) and MRP14
(S100A9) are members of the S100 family of calcium-
modulated proteins that regulate myeloid cell function and
control inﬂammation [141]. Proteasome activator complex
subunit 2 is required for immunoproteasome assembly
and eﬃcient antigen processing [137]. IL-12 p40 is a pro-
inﬂammatory cytokine with an important role in innate
and adaptive immunity [142, 143]. The protein encoded
by the IL-12B gene, which is a susceptibility locus in CD and
UC [144, 145]. Caspase activation and recruitment domain-
(CARD-) and pyrin domain- (PYD-) containing proteins
promote caspase-mediated apoptosis predominantly through
the activation of caspase 9 [137]. The key structural scaﬀold
for inﬂammasome (plays a role in host defence against
microbial pathogens and gut homeostasis) assembly is com-
posed of ﬁlaments of PYD and CARD in the sensor, adaptor,
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and eﬀector components [146]. Dismutase delivers copper to
copper-zinc superoxide dismutase [137].
The decrease of proapoptosis proteins and the increase
of antiapoptosis proteins shown in this study may contrib-
ute to the inhibition of the lymphocyte apoptosis, which
subsequently result in the overactivation of lymphocytes in
colitis rats. Lymphocyte homeostasis/apoptosis is pivotal
in orchestrating eﬃcient immune responses and avoiding
autoimmunity [147]. Liu et al. raised concerns about some
limitations in the study including diﬃculty analyzing some
membrane proteins and low-abundance proteins by 2D
PAGE, as well as poor reproducibility and variations of
spot intensity observed with silver staining as previously
described [148].
In a murine model of CD using multidrug resistance-
targeted mutation (Mdr1a−/−) mice, Barnett et al. investi-
gated the eﬀect of polyphenol-rich green tea extract (GrTP)
on the inﬂamed mouse colon transcriptome and proteome
[149]. Transcriptomic data (whole genome microarray)
and the proteomic analysis 2DE/LC-MS technique were
performed in parallel on the same samples. Integration of
the data show reduced abundance of transcripts and proteins
associated with immune and inﬂammatory response as well
as ﬁbrinogenesis pathways and increased abundance of
those associated with xenobiotic metabolism pathways in
response to GrTP [149]. Increased abundance of peroxi-
some proliferator-activated receptor-α (PPAR-α) and
decrease in signal transducer and activator of transcription
1 (STAT-1) protein abundance appeared to be the two key
modulatory eﬀects in response to GrTP in Mdr1a−/− mice.
Dietary intake of polyphenols derived from green tea was
demonstrated to ameliorate intestinal inﬂammation in the
colon of a mouse model of CD and therefore may play a
part in an overall IBD treatment regimen [149]. PPARs
are ligand-activated transcription factors of the nuclear hor-
mone receptor superfamily [150]. PPARs play essential
roles in the regulation of cellular proliferation and diﬀerenti-
ation, atherosclerosis, inﬂammation, metabolism, infertility,
tumourigenesis, and demyelination [151–153]. PPAR-α is
expressed at high levels in organs with signiﬁcant catabolism
of fatty acids and is also shown to have a role in control-
ling colonic inﬂammation and mucosal tissue homeostasis
[150, 154, 155]. In addition to the important role of NF-
κB and MAPK inﬂammatory pathways in IBD, many cyto-
kines exert their intracellular signalling by activating the
JAK/STAT pathway [156]. Overexpression and activation
of STAT1 have previously been linked to IBD relapse
[157]. The beneﬁcial eﬀects of GrTP in this study could
be due to the speciﬁc anti-inﬂammatory eﬀect of the com-
pound on this particular genetic defect of IBD mouse
model (Mdr1a−/−).
4.8. Organelle Proteomics (Subproteomics) in Inﬂammatory
Bowel Disease. Complexity and abundance of proteins with
very variable concentrations and dynamic range have a sig-
niﬁcant impact in the sensitivity of cellular proteomic meth-
odologies [77]. Subcellular fractionation and proteomics
(subproteomics) are an ideal adjunct for reducing cellular
sample complexity; it can combine current proteomic
methodology for enrichment and analysis of intracellular
organelles and low-abundance multiproteins [158].
Subcellular fractionation involves disruption of the
cellular assembly (homogenisation) followed by fraction-
ation of the homogenate to diﬀerent subgroups, based on
their physical properties, by using diﬀerential centrifugation
disruption; moreover, quality control methods including
quantitative western blotting (targeting speciﬁc organelle-
marker proteins) and qualitative/morphological analysis
(electronmicroscopy) can ensure optimal subcellular fraction-
ation of interest [158]. Although absolute subcellular compart-
ment puriﬁcation is not possible due to cofractionation of
particles with similar physical characteristics, this method is
a powerful adjunct to the proteomic analysis [158, 159].
4.9. Cell Line Studies on Organelles.One of the early reports of
organelles proteomic application cells was by Fialka et al., who
coupled subcellular fractionation with 2D PAGE, immuno-
blotting and microsequencing for investigation of endosomal
proteome as method for analysis of epithelial cells [160].
4.10. Human Studies Using Subcellular Fractions. O’Morain
et al. carried out subcellular fractionation on rectal biopsies
taken from patients with UC, Crohn’s colitis, and CD with
no rectal involvement as well as normal controls by homog-
enizing samples in isotonic sucrose followed by sucrose den-
sity gradient centrifugation [161]. The gradient fractions and
tissue homogenates were then assayed for marker enzymes
for the plasma membrane (5′-nucleotidase), mitochondria
(malate dehydrogenase), peroxisomes (catalase), cytosol
(lactate dehydrogenase), lysosomes (N-acetyl-beta-glucosa-
minidase), and endoplasmic reticulum (neutral-alpha-gluco-
sidase); they found selective and speciﬁc alterations in the
principal subcellular organelles, especially the plasma mem-
brane, lysosomes, and mitochondria in IBD [161].
In a comparative study exploring diﬀerential protein
expressions in cellular compartments of IEC (nuclei, mem-
branes, and cytosols) in CD patients versus control, Nanni
et al. isolated epithelial cells from surgically resected colonic
tissue using a previously conﬁrmed method [162] and utilised
mono-dimensional gel electrophoresis (1DGE) combined
with label-free nano-LC ESI/QTOF MS followed by targeted
MS/MS analysis [73]. Annexin A1 (a nuclei membrane pro-
tein regulating phospholipase A2 activity) and malate dehy-
drogenase (a mitochondrial and cytosolic enzyme involved
in the citric acid cycle as well as malate-aspartate shuttle
[74]) were decreased in abundance in CD patients in compar-
ison to controls. Protein increases were identiﬁed in each of
the subcellular fractions. Examples include ubiquitin, tryp-
tase precursor, heat shock 70kDa protein-5, and ATP syn-
thase beta. Increased levels of ubiquitin in the nuclear
fraction were proposed to reﬂect increased activity of IECs,
consistent with increased levels of ATP synthase subunit
beta in the membrane fraction [73]. Heat shock 70kDa
protein-5 is a multifunctional protein that participates in
protein folding and calcium homeostasis and serves as an
essential regulator of ER stress response [163]. This protein
was increased in abundance in the membrane fraction of
CD patients, as might be expected due to its role in the
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protection of the intestinal epithelium [73]. Tryptase (a ser-
ine protease also known as mast cell tryptase) has been
shown to play an important role in acute DSS-induced coli-
tis in mice [164].
Most of the proteins found in the study by Nanni et al.
[155] were similar to those found in the earlier diﬀerential
protein proﬁling study on IEC from IBD patients using 2D
PAGE/MS methodology [81], thereby conﬁrming these
results. Heat shock proteins (Hsp) are considered chaperone
proteins involved in the folding process of other cellular pro-
teins [165]. Their expressions are increased in abundance in
response to intracellular stresses including hyperthermia,
ischemia/reperfusion, oxygen radicals, heavy metals, ethanol,
and amino acid analogues [165]. Although upregulation of
Hsp70 seems to be a natural response to inﬂammation as
per Nanni et al., a previous study by Hu et al. contradicts this
ﬁnding by showing that inducible Hsp expression (Hsp25/27
and Hsp70) is translationally (but not transcriptionally)
decreased in abundance via phosphorylation and inactiva-
tion of eukaryotic initiation factor-2α (eIF-2α) in active
IBD [166].
4.11. Secretome. Proﬁling and identiﬁcation of active serine
proteases secreted by the colonic mucosa of control and
IBD patients was performed using a MS-based functional
proteomic analysis to monitor availability of enzyme active
sites in colonic tissues from CD or UC patients. The study
employed activity-based probes, chemical proteomic tools,
which possess a reactive group to mimic enzymatic substrate
and covalently bind active proteases. Biotinylation of the
ABP allows selective avidin-based aﬃnity capture of the
ABP-enzyme target, which is identiﬁed by MS and post-
tryptic digestion to generate peptides for LC-MS/MS anal-
ysis. Seven serine proteases including cathepsin G, plasma
kallikrein, plasmin, tryptase, chymotrypsin-like elastase 3A,
thrombin, and aminopeptidase B were identiﬁed, of which
cathepsin G and thrombin were overactive in IBD patient
samples compared to healthy controls [167]. These data
are consistent with the earlier study by Dabek et al. reporting
the increased presence of cathepsin-G in faeces of UC
patients [168].
4.12. Intermediate Filaments. Intermediate ﬁlaments (IF) are
one of the main components of the human cell cytoskeleton,
which mainly consist of keratins (K). K8, K18, and K19 are
the main keratins in the intestinal epithelial cells. Keratin
alteration may play a role in the pathophysiology of ulcera-
tive colitis (UC). K8−/− mice develop chronic colitis via a
mucosal chronic T-helper type 2 inﬂammatory response
[169]. K8 and K18 play a role in TNF-α-induced apoptosis
[170, 171]. A recent study by our group (Corfe et al.)
exploited the subcellular fractionation technique to identify
diﬀerential expression of intermediate ﬁlaments (IF) in UC
patients at diﬀering risk for colorectal cancer [172]. Colonic
biopsies were collected endoscopically from the following
patients: recent-onset colitis in remission (n = 8), long-
standing pancolitis in remission (n = 10), and UC with
PSC (n = 6). UC with dysplasia (both from the dysplastic
lesion and distal rectal mucosa; n = 3), active distal UC
(n = 10), proximal inactive mucosa from the same patients
with active UC, and normal controls (n = 10) were also
included. The IF fraction was prepared for quantitative anal-
ysis using iTRAQ. Signiﬁcant diﬀerences in protein abun-
dance were followed by immunoblotting and IHC. Acute
inﬂammation resulted in reduced K8, K18, and K19 and
vimentin (VIM) compared to controls and noninﬂamed
proximal mucosa; reduced levels of IF–associated proteins
were also seen in UC with PSC and UC with dysplasia (both
from the lesion and remote distal rectal mucosa). Increased
levels of K8, K18, and K19 and VIM in longstanding panco-
litis in remission were noted relative to controls and recent-
onset colitis in remission [172]. Increased expression of
VIM, generally expressed in cells with a mesenchymal phe-
notype in longstanding pancolitis, may reﬂect morphological
colonic tissue remodelling and architectural alterations,
reﬂecting the chronic relapsing/remitting course of the dis-
ease as a consequence of accumulated damage during each
active phase [173, 174]. We proposed a model for the patho-
genesis of colitis-associated colorectal cancer (CAC) whereby
acute inﬂammation reduces keratin levels and aﬀects muco-
sal IF protein integrity which lags behind apparent clinical,
microscopic, and endoscopic recovery; persistent failure of
such recovery may be the cornerstone of pathogenesis of
CAC [172]. It should be emphasised that this study was
cross-sectional with limited patient number especially in
the cancer risk groups (UC with PSC and dysplasia).
A brief description of each of the reviewed proteomic
studies is provided in Table 2.
5. Conclusions
The human proteome surpasses the human genome by
several orders of magnitudes with regard to complexity,
dynamic range, and diagnostic capability [175]. New proteo-
mic high-throughput technologies together with advances
in bioinformatics science provide a great opportunity for
exploring complex human conditions such as autoimmune
disease and cancer. Despite many advances in understand-
ing the IBD disease process over the past decade, mainly
due to Human Genome Project and knockout gene tech-
niques in animal model studies, the exact pathogenesis of
IBD remains elusive.
The combination of a very large number of cellular pro-
teins with highly variable concentration together with their
susceptibility to enzymatic degradation and precipitation
makes proteomics a challenging area of investigation. Never-
theless, careful sample selection, meticulous attention during
fractionation of proteins, development of more speciﬁc sub-
proteomic techniques to diminish the masking eﬀect of high
abundance proteins while enhancing the detection rate of low
abundance ones, and ﬁne-tuning of proteomic methodology
together with future proteomic technology developments can
improve protein uptake and reproducibility.
In summary, proteomic technologies combined with bio-
informatics analysis are very useful yet underexploited tools
in exploring complex disease processes such as IBD in terms
of delineating its pathophysiology, as well as discovering key
biomarkers of disease activity/remission, optimizing risk
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Table 2: High-throughput proteomic studies in IBD.
Proteomic
studies in
IBD
References Analytical technique(s)
Type of study
(cell line, animal,
human)
Signiﬁcant ﬁnding(s)
Bioﬂuid
proteomics
Meuwis et al.
2007 [50]
SELDI-TOF-MS Human
Identiﬁcation of PF4, MRP8, FIBA, and Hpa2 as
potential biomarkers of disease activity in IBD
Meuwis et al.
2008 [61]
SELDI-TOF-MS Human
Positive correlation between PF4 level and
nonresponse to inﬂiximab therapy in CD
Kanmura et al.
2009 [62]
Protein array technology
coupling ProteinChip
system with
SELDI-TOF/MS
Human
Identiﬁcation of 3 increased in abundance proteins
(HNP 1–3) in the serum of active UC patients as
new biomarkers of UC disease activity
Hatsugai et al.
2010 [71]
2DE, discriminant
analysis (OPLS-DA),
and MALDI-TOF MS/MS
Human
Identiﬁcation of a panel of proteins that could
discriminate between UC and CD including
ANXA6, PRDX2, ABHD14B, cyclophilin A,
CA2, ACTB, and S100A9
Gazouli et al.
2013 [72]
2DE and MALDI-TOF-MS Human
Identiﬁcation of a panel of increased in abundance
proteins in the primary inﬂiximab nonresponsive
patients including: APOA1, APOE, CO4B, PLMN,
TRFE, APOH, and CLUS in comparison to
inﬂiximab-induced remission patients
Vaiopoulou et al.
2015 [63]
2DE and MALDI-TOF-MS Human
Overexpression of ceruloplasmin and apolipoprotein
B-100 (APOB) in children and clusterin in adults
with CD
Viennois et al.
2015 [76]
2DE and MALDI-TOF/TOF
MS
Murine
Identiﬁcation of altered expression of proteins
speciﬁc to intestinal inﬂammation development
(PZP, COL1A1, and PRDX2), IL10−/− murine
model inﬂammation (PZP, PRDX2), arthritic
inﬂammation development (serum amyloid
P-component and transthyretin), and nonspeciﬁc
inﬂammation (HP, ITIH4, HPX, C3, and A1BG)
Tissue
proteomics
Barcelo-Batllori
et al. 2002 [131]
2DE and MALDI-TOF-MS
Cell line
and human
Increase of indoleamine-2,3-dioxygenase
in the puriﬁed IEC from IBD patients relative
to normal controls
Hsieh et al.
2006 [99]
2DE and MALDI-TOF-MS Human
Identiﬁcation of 19 altered proteins expression
(13 decreased in abundance and 6 increased in
abundance) in the active compartment of UC
mucosa relative to control. Altered regulation
of mitochondrial proteins raising the possibility
of mitochondrial dysfunction in UC
Liu et al.
2007 [137]
2DE, MALDI-TOF-MS,
and real-time RT-PCR
Murine
Alteration of a series of apoptosis-related
proteins (increased in abundance IL-12 p40
and decreased in abundance CARD, PYD
domain-containing protein, and proteasome
activator complex subunit 2), proteins involved
in cell growth, diﬀerentiation, and signal
transduction (increased in abundance
NDPKs and E2N), inﬂ ammatory factors
(increased in abundance MRP14), and
metabolism/oxidative stress response-related
proteins (increased in abundance ATP-citrate
synthase, phosphoglycerate mutase, and dismutase)
in lymphocytes from a rat colitis model
Shkoda et al.
2007 [81]
2DE and
MALDI-TOF MS
Human
Identiﬁcation of several diﬀerentially
expressed proteins in the IEC from active IBD
patients relative to controls (including L-lactate
dehydrogenase, NADPH prostaglandin
E2 reductase, keratin 19, and Rho GDI α)
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Table 2: Continued.
Proteomic
studies in
IBD
References Analytical technique(s)
Type of study
(cell line, animal,
human)
Signiﬁcant ﬁnding(s)
Fogt et al.
2008 [92]
2DE and LC-MS/MS Human
Identiﬁcation of increased expression of proteins
that are mainly involved in inﬂammation and
repair (proto-cadherins, α-1 antitrypsin,
tetratricopeptide repeat domains, caldesmon,
and mutant desmin) in the active UC tissue
relative to the inactive proximal mucosa
Brentnall et al.
2009 [121]
HPLC, Q-TOF MS/MS,
and iTRAQ labelling
Human
Identiﬁcation of diﬀerential protein expression
relating to mitochondria (CPS1 and S100P)
associated with UC neoplastic progression
Araki et al.
2009 [129]
2DE and LC-MS/MS
Cell line
and human
Identiﬁcation of overexpression of HSP47 in
UC-associated cancer relative to sporadic colon
cancer tissues
May et al.
2011 [126]
Label-free LTQ-Orbitrap
hybrid MS coupled
with HPLC
Human
Identiﬁcation of two diﬀerentially expressed
mitochondrial proteins (TRAP1, CPS1) associated
with UC neoplastic progression, which was found
in both dysplastic and nondysplastic tissues
Zhao et al.
2011 [117]
2DE and MALDI
TOF/TOF MS
Human
Detecting P-p38 increase and MAWBP/
galectin-3 decrease in active UC compared
to normal controls; proposing P38 MAPK pathway
involvement in UC disease activity
M’Koma et al.
2011 [78]
Histology-directed
MALDI-MS
(tissue imaging)
Human
Discriminatory colonic submucosa proteomic proﬁle
between UC and Crohn’s colitis via investigation of
MS spectral peaks
Poulsen et al.
2012 [102]
2DE and MALDI-TOF
MS together with PCA
analysis
Human
Identiﬁcation of 33 individual proteins with altered
expression in the active UC mucosa relative to
proximal inactive mucosa including proteins
involved in energy metabolism (triosephosphate
isomerase, glycerol-3-phosphate-dehydrogenase,
alpha enolase, and L-lactate dehydrogenase B-chain)
and in oxidative stress (superoxide dismutase,
thioredoxins, and selenium-binding protein)
Kwon et al.
2012 [115]
2DE and
MALDI-TOF/TOF MS
Human
Identiﬁcation of 3 proteins with altered expression
in UC and tuberculous colitis (TC) (mutant β-actin,
α-enolase, Charcot-Leyden crystal) relative to
control, suggesting α-enolase as a candidate
biomarker for diﬀerential diagnosis of TC and UC
Barnett et al.
2013 [149]
2DE and LC-MS Murine
Reduced abundance of proteins associated with
immune and inﬂammatory response as well as
ﬁbrinogenesis pathways, and increased abundance
of those associated with xenobiotic metabolism
pathways in response to GrTP
Seeley et al.
2013 [80]
Histology-directed
MALDI-MS
(tissue imaging)
Human
Identiﬁcation of a support vector machine algorithm
consisting of 25 peaks able to diﬀerentiate spectra
from CC and UC with 76.9% spectral accuracy
Han et al.
2013 [104]
Label-free LC-MS Human
Suggestion of 3 proteins as potential biomarkers
for active CD, including PRG2, LCP1, and PSME1
Zhou et al.
2013 [128]
2DE, WB, and
MALDI MS
Human
Identiﬁed 6 diﬀerentially expressed proteins
(prohibitin, calreticulin, apolipoprotein A-I,
intelectin-1, protein disulphide isomerase, and
glutathione s-transferase Pi) in active CD mucosa
relative to the adjacent normal-looking mucosa
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stratiﬁcation for tailored individualized treatment, and
revealing noninvasive predictors of evolution to CAC.
Improved biomarkers remain an unmet need in inﬂamma-
tory bowel disease (IBD) [176]. The use of biomarker panels
has higher discriminatory ability than that of single protein
markers. As an example, Starr et al. identiﬁed two biomarker
panels for paediatric patients to diﬀerentiate ascending colon
biopsies of CD from healthy control patients and UC from
CD [177]. These biomarkers have recently been further con-
ﬁrmed in intestinal mucosal–luminal interface aspirates and
stool. In terms of clinical translation, a key ﬁnding from this
study is that the biomarkers demonstrate transferable results
in stool samples providing a scope for noninvasive sampling
for biomarker analysis samples [178]. Regulatory authorities
have mandated the use of patient-reported outcomes for
inclusion as an outcome measure in inﬂammatory bowel dis-
ease trials. However, as recently noted by Khanna et al., it is
likely that CRP and FCP will continue the usage in clinical
trials as a secondary end point or to stratify baseline dis-
ease severity; noninvasive biomarkers are yet to replace
endoscopy review data [179]. In terms of personalised
medicine, it is important to understand the translatability
and variability of individual biomarkers for development of
tools such as quantitative system pharmacology models to
predict individual response [180]. Development in sample
fractionation and MS technologies are providing step change
to research in personalised medicine [181]. These include
high-throughput fractionation systems with minimal han-
dling and sample loss [182, 183]. Also, newMS developments
such as BoxCar data acquisition [184] and parallel accumula-
tion–serial fragmentation [185] can yield high coverage and
dynamic range, for example, 90% coverage of the proteome
of a human cancer cell line (>6200 proteins) [184, 185].
The biomarker ﬁeld is however developing, but work is still
Table 2: Continued.
Proteomic
studies in
IBD
References Analytical technique(s)
Type of study
(cell line, animal,
human)
Signiﬁcant ﬁnding(s)
Bennike et al.
2015 [113]
Label-free (LFQ)
proteomic analysis
Human
Comparing UC to normal biopsies identiﬁed proteins
with statistically signiﬁcant altered abundance in the
UC biopsies to be from neutrophils and associated
with the formation of neutrophil extracellular traps
(NETs) suggesting stimulation of innate immunity.
Organelle
proteomics
O’Morain et al.
1985 [161]
2DE and MS Human
Identiﬁcation of speciﬁc alterations in the principal
subcellular organelles, especially the plasma
membrane, lysosomes, and mitochondria in IBD
in comparison to control
Nanni et al.
2009 [73]
1D SDS-PAGE and
nano-LC ESI/Q-TOF-MS
with targeted MS/MS
analysis
Human
Identiﬁcation of certain decreased in abundance
(Annexin A1, malate dehydrogenase) and
increased (diﬀerent histones and ubiquitin in
the nuclear fraction; tryptase alpha-1 precursor in
the cytosolic fraction; ATP synthase subunit beta
and heat shock 70 kDa protein-5 in the fraction
containing membranes) proteins in CD patients
relative to controls
Nanni et al.
2009 [212]
LC ESI/Q-TOF-MS
with targeted MS/MS
analysis
Human
Suggestion of a speciﬁc serum exoprotease
activity with proinﬂammatory properties in CD
Corfe et al.
2015 [172]
HPLC, ESI/Q-TOF
MS-MS, and
iTRAQ labelling
Human
Reduced levels of K8, K18, and K19 and vimentin
(VIM) in acute distal UC mucosa compared to
controls and noninﬂamed proximal mucosa; reduced
levels of IF–associated proteins in UC with PSC and
UC with dysplasia; increased levels of K8, K18, and
K19 and VIM in longstanding pancolitis in
remission relative to controls and recent-onset
colitis in remission
Denadai-Souza
et al.
2018 [167]
MS-based functional
proteomic analysis
employing
activity-based probes
Human
Proﬁling and identiﬁcation of active serine proteases
were performed to monitor availability of enzyme
active sites in colonic tissues from CD or UC patients.
Seven serine proteases including cathepsin G, plasma
kallikrein, plasmin, tryptase, chymotrypsin-like
elastase 3A, thrombin, and aminopeptidase B
were identiﬁed, of which cathepsin G and thrombin
were overactive in IBD patient samples compared
to healthy controls.
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required to translate biomarkers from proteomic analysis to
clinical utility.
6. Future Perspectives
Depositing and mining data from the proteomic repositories
such as the PRoteomics IDEntiﬁcations (PRIDE) database
and archive has the potential to enable integration of interre-
lated IBD studies, systematic review, and the meta-analysis of
the raw data. These data can then be linked to diﬀerent path-
way/protein interaction databases such as “Reactome” and
“String” to further enhance our knowledge on the complex
pathophysiology of IBD. This cycle is of course interactive
and could lend into the possibility of discovering new cellular
pathways as well as new functional roles for existing proteins,
which can be further conﬁrmed through targeted methodol-
ogies. An example of the value is the study of Kirov et al. who
analysed the proteomics raw data deposited to the Proteo-
meXchange Consortium via the PRIDE ProteomXchange
repository with the dataset identiﬁer PXD001608 [186]. The
ﬁndings of the(ir) initial publication (Bennike et al. [113])
were developed further by integrating published tran-
scriptome data which indicated compensatory regulation at
transcription levels of the ECM proteins. Key protein
changes were conﬁrmed by immunoblot analysis [186]. In
terms of integrating omic data sets, there are two methods
of data integration: horizontal and vertical meta-analyses
which integrate multiple data sets of a similar type or of dif-
ferent types, e.g., transcriptomics and genomics [187]. Inte-
grating datasets require careful assessment of compatibility
(sample type, data format, and clinical metadata). For ohmic
data sets, similar considerations apply with the added caveat
that corresponding time points may not be appropriate as
changes in mRNA are not necessarily concurrent or in the
same direction of change to proteomic or metabolomics data.
It is increasingly recognised that proteoforms of individ-
ual proteins, arising from the combination of sequence vari-
ants and posttranslational modiﬁcations (including cleavage
products), can be altered in level with respect to the speciﬁc
disease state [172, 188]. This requires more exploration in
IBD and the application of top-down methods as exempliﬁed
by analysis of speciﬁc proteoforms associated with Alzhei-
mer’s disease [189].
It is well recognised that proteome analysis, while of
value, should be integrated with GWAS, epigenomic, tran-
scriptomic, metabolomic, and microbiomic information to
build a comprehensive molecular map of IBD. In terms of
the microbiome, the emerging ﬁeld of metaproteomics is
enabling understanding of the host-microbiome in relation
to IBD pathogenesis and microbial management-based
therapeutic strategies. There are considerable technical chal-
lenges resulting in part from the complexity arising from
studying, in eﬀect, multiple species from the same sample:
hundreds of bacterial species may be present in varying
amounts within the clinical sample. Considerable progress
has been made, as reviewed by Starr et al. [190]. A key
development in proteomic tools includes the stable isotopi-
cally labelled microbiota (SILAMi) technique to study intes-
tinal metaproteomes [191] and the MetaPro-IQ database
for high-eﬃciency protein identiﬁcations of gut microbiome
samples [192]. Development of tools to determine relation-
ships between gut microbiomes, particularly transkingdom
correlation analysis of mitochondrial protein expression,
enabled the investigation of whether intestinal microbiomes
associated with CD are causative or reﬂective of chronic
long-term inﬂammation. The proteomic ﬁndings indicated
mitochondrial dysfunction with downregulation of proteins
implicated in H2S detoxiﬁcation while the relative abun-
dance of H2S microbial producers is increased. The bacte-
rium, A. parvulum, which induces colitis in vivo in IBD IL-
10-deﬁcient mice (a mouse model of IBD) was demonstrated
as a central hub of H2S production, with disease only occur-
ring in the presence of other commensal microbiota [193].
Further metaproteomic analysis of mucosal luminal interface
aspirates reveals that microbial proteins related to oxidative
stress responses are upregulated, in intestinal extracellular
vesicles of IBD cases, which correlate with abnormal host-
microbiota interactions [194]. Metatranscriptomics can pro-
vide complementary insights into community interactions
and disease-speciﬁc alterations.
In terms of biomarker panels, biomarkers can be mol-
ecules other than proteins; an example is mitochondrial
(mt) DNA which is a potential mechanistic biomarker,
with mtDNA-TLR9 proposed as a therapeutic target in
IBD [195]. N-Formylated peptides were also identiﬁed by
MS in this same study of intestinal mucosal mitochondrial
damage and mtDNA release in active IBD. IgG Fc-
glycosylation status has also been proposed for biomarker
purposes [196].
In terms of clinical translation, state-of-the-art MS
instrumentation is often more suited to research than clin-
ical labs, but portable rapid nanosensing and monitoring
platforms are coming online, as exempliﬁed for detection
and quantiﬁcation of two tuberculosis-speciﬁc biomarkers
(CFP-10 and ESAT-6) in blood samples [197]. Novel assays
such as the proximity extension assay (PEA) enable rapid
sample proﬁling which utilises the high sensitivity and spec-
iﬁcity of polymerase chain reaction. This one-step, multiplex
protein quantiﬁcation method uses a pair of DNA oligonu-
cleotides linked to antibodies directed to the target protein.
The value of the approach has been demonstrated for detec-
tion of colorectal neoplasias [198] which has been applied to
develop serum biomarker signatures for IBD, as part of the
IBD Character Consortium (https://cordis.europa.eu/project/
rcn/106191/reporting/en). In general, MS methods can com-
plement traditional antibody-based methods and provide
an alternative where antibodies are not available with
potential for multiplex analysis for monitoring multiple pro-
teins/sample that arise from discovery-based experiments:
from proteomics, transcriptomics, and metaproteomics.
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